FDA Announces Public Meeting to Gather Input on Risk Evaluation and Mitigation Strategies for Drugs and Biological Products

Summary

The Food and Drug Administration (FDA) is hosting a 2-day public meeting to gather input from stakeholders on the development and implementation of risk evaluation and mitigation strategies (REMS) for drugs and biological products, following concerns raised by various stakeholders about the impact of REMS on the healthcare system and individual prescribers.